CD19 and acute lymphoblastic leukemia: Transfusion of CAR-T cells targeting CD19 to treat relapsed B-cell acute lymphoblastic leukemia ALL (B-ALL) and certain types of relapsed non-Hodgkin's lymphoma obtain as high as 70–90% clinical complete response rates.